Program
HRS-9821
A development code. Also written as “HRS-9821 Powder for Inhalation/HRS-9821 inhalation suspension”, “HRS-9821 Inhalation Suspension” and “HRS-9821 Powder for Inhalation”.
In Jiangsu HengRui Medicine's pipeline, PDE3/4
. Its studies are mostly in Pulmonary Disease, Chronic Obstructive, led by Jiangsu HengRui Medicine.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 42 open or running | phase 2since Jun 1, 2026 | Nov 14, 2022 | none ahead |
- Named in Jiangsu HengRui Medicine’s own pipeline as
HRS-9821
, phase 2, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 14, 2022First study: phase 1 study in Pulmonary Disease, Chronic ObstructiveFirst studyNCT05622864 · 106 enrolled · China
- Jul 22, 2025Phase 1 study in Pulmonary Disease, Chronic ObstructiveNCT07116915 · 85 enrolled · China
- Apr 28, 2026Phase 1 study in Pulmonary Disease, Chronic ObstructiveNCT07567872 · 48 planned · China
- Jun 1, 2026Phase 2 study in Pulmonary Disease, Chronic ObstructivePhase 2 reachedNCT07640451 · 90 planned · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07640451Pulmonary Disease, Chronic Obstructive · China | 2 | Recruiting | Oct 2026 | 90 |
| NCT07567872Pulmonary Disease, Chronic Obstructive · China | 1 | Recruiting | Sep 2026 | 48 |
| NCT07116915Pulmonary Disease, Chronic Obstructive · China | 1 | Completed | Aug 14, 2026 | 85 |
| NCT05622864Pulmonary Disease, Chronic Obstructive · China | 1 | Completed | May 7, 2025 | 106 |
How it is read
Names in the registry
- “HRS-9821 Powder for Inhalation/HRS-9821 inhalation suspension”, 2 entries
- “HRS-9821”, 2 entries
- “HRS-9821 Inhalation Suspension”, 1 entry
- “HRS-9821 Powder for Inhalation”, 1 entry
Codes read as this program: HRS9821.
Conditions, from the studies’ own filings
- Pulmonary Disease, Chronic Obstructive, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.